Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 April 2024 | Story Andre Damons | Photo SUPPLIED
Five registrars from the Department of Internal Medicine
The five MMed students from the Department of Internal Medicine at the University of the Free State (UFS) will represent the university at international events. Drs Paul Bester, Anri Gerber, Debi Moagi, Batandwa Ntantiso, and Tahlia Mohangi.

Five registrars and MMed students from the Department of Internal Medicine within the School of Clinical Medicine at the University of the Free State (UFS) will soon jet off to participate in prestigious international events where they will present research in their respective fields.

Drs Paul Bester, Anri Gerber and Debi Mmasabata Seriti Moagi will attend the prestigious 9th McMaster International Review Course in Internal Medicine (MIRCIM) in Kraków, Poland in May. MIRCIM is a joint educational initiative of McMaster University’s Department of Medicine — the birthplace of evidence-based medicine (EBM) and problem-based learning (PBL) — and the Polish Institute for Evidence Based Medicine.

Dr Gerber, together with Dr Bathandwa Ntantiso, will also attend the Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA) NATA24 Annual Symposium in Bologna, Italy, scheduled from 18 to 20 April 2024. NATA24 is a unique meeting: a global multidisciplinary forum gathering healthcare professionals seeking to learn more about best clinical practice in patient blood management (PBM), the management of anaemia and iron deficiency, critical bleeding and thrombosis.

Another registrar, Dr Tahlia Mohangi, a third-year registrar in the Department of Internal Medicine, is poised to showcase her research at the upcoming International Society of Blood Transfusion (ISBT) Congress in Barcelona, Spain, in June.

Prof Thabiso Mofokeng, Head of the Department of Internal Medicine, as well as Dr Claire Armour (Barrett), Head: Research and Development in the School of Clinical Medicine, say they are extremely proud of the registrars for their exceptional international contribution. 

Academic excellence

According to Dr Armour (Barrett), Dr Bester, who passed his MBChB cum laude, is a shining example of academic excellence and passion for medicine. His journey is deeply rooted in his personal experience as a type 1 diabetic since childhood.

“Dr Bester’s commitment to excellence is evident in his academic achievements, having passed the primary exams of the Colleges of Medicine of South Africa with distinction. His dedication to medicine extends beyond the classroom, as he actively seeks to unravel complex medical mysteries and rare disease presentations.

“Dr Bester’s participation in MIRCIM is testament to his commitment to advancing medical understanding in his country and beyond. His dedication, coupled with his personal experience and academic achievements, makes him a role model for aspiring medical professionals. Dr Bester is truly a credit to his alma mater (the UFS) and a source of pride for South Africa,” she says.

Dr Bester will present his compelling case report, “Protein losing enteropathy in a young patient with chorea”, at MIRCIM with his presentation not only showcasing his diagnostic acumen but also highlights his determination to share knowledge and contribute to the medical community. His trip to MIRCIM is sponsored by the esteemed Faculty of Consulting Physicians of South Africa (FCPSA).

Passion for research and patient care

Dr Gerber, who has a passion for research and patient care, has been selected to present her research, “Ironing out the Iron Profile in Heart Failure Patients”, at the NATA24 Congress before jetting off to the MIRCIM 2024 Congress where her case report, “Takayasu Arteritis: A clot or not”, has been accepted for an oral presentation. She will also compete in the prestigious Best Case Report Contest, a testament to her clinical acumen and research skills.

Last year she also attended the prestigious NIH Fogarty “Scientific Writing and Manuscript Preparation Course” presented by the University of Cape Town and University of California (San Francisco), an experience that greatly enhanced her research endeavours. In 2023, she was awarded first place in the Three Schools of Medicine Real Short Registrars Research Competition (UFS) in June 2023, where she presented the preliminary results of her MMed research.

“Dr Gerber's accomplishments exemplify her dedication to advancing medical knowledge and improving patient outcomes. Her future is bright, and she is poised to make significant contributions to the field of medicine,” says Dr Armour (Barrett).

Diagnosing rare diseases

Dr Moagi, who is deeply committed to advancing medical knowledge and patient care, will be presenting a compelling case report entitled “Unveiling the Rarity: Bilateral Embryonal Rhabdomyosarcoma Causing Kidney Failure in a Young Adult”, in Kraków, Poland.

Under the guidance of her esteemed supervisor, Prof Busiswa Feziwe Bisiwe, Dr Moagi’s case report sheds light on the challenges of diagnosing rare diseases, emphasising the importance of considering alternative diagnoses. Her case report highlights how embryonal rhabdomyosarcoma of the kidneys can masquerade as genitourinary tuberculosis, underscoring the need for a comprehensive approach to diagnosis and treatment.

According to Dr Armour (Barrett), this case report not only underscores Dr Moagi’s commitment to advancing medical knowledge and improving patient outcomes but also exemplifies the collaborative efforts within the medical community. Sponsored by the Faculty of Consulting Physicians of South Africa (FCPSA), her participation in MIRCIM is a testament to her dedication in the field of Internal Medicine. Dr Moagi was awarded a distinction for the research component of her MMed degree and continues to shape the future of healthcare through research, exemplifying excellence in her field. She is also the first black African to pass the UFS MBCHB with distinction.

Groundbreaking research

Dr Ntantiso’s groundbreaking research, “Anaemia in General Medical Inpatients in Bloemfontein, South Africa: A Significant Public Health Concern”, has been chosen for presentation as a poster at the prestigious NATA24 Annual Symposium. His travel expenses have been generously funded by the Three Schools of Medicine and the Department of Internal Medicine.

His exceptional research has not only been recognised locally but has also garnered international acclaim. He also participated in the NIH Fogarty Program’s “Scientific Writing and Manuscript Preparation Course”. Leveraging this opportunity, he refined his manuscript, leading to the successful completion of the research component of his Master of Medicine in Internal Medicine with distinction in March 2024. Currently, he is preparing for his final examinations for the Fellowship of the College of Physicians.

“In addition to his recent achievements, Dr Ntantiso was awarded third place in the Three Schools of Medicine Real Short Registrars Research Competition (UFS) in June 2023. The impact of his research has been profound, shedding light on the prevalence of anaemia in medical patients and emphasising the critical need to assess the local prevalence of anaemia within specific patient populations,” says Dr Armour (Barrett).

Exploring anaemia

Dr Tahlia Mohangi’s research study, “A 5-year Retrospective Database Review of Anaemia Prevalence and Associated Laboratory Biomarkers in a Central South African Setting”, explores anaemia and its correlation with various laboratory biomarkers. She has been awarded the prestigious Harold Gunson Fellowship from the International Society of Blood Transfusion (ISBT) to attend the congress.

“Her research endeavours to redefine the approach to anaemia in internal medicine patients while also shedding light on its alarming prevalence within the local community,” says Dr Armour (Barrett).

Dr Mohangi’s research career was boosted when she also attended a NIH Fogarty “Scientific Writing and Manuscript Preparation Course”. She came second in the Faculty of Health Sciences Three Schools of Medicine Real Short Registrars Research Competition (UFS) in June 2023, where she presented the protocol of her MMed research.

News Archive

Research contributes to improving quality of life for cancer patients
2016-11-21

Description: Inorganic Chemistry supervisors  Tags: Inorganic Chemistry supervisors

Inorganic Chemistry supervisors in the Radiopharmacy
Laboratory during the preparation of a typical complex
mixture to see how fast it reacts. Here are, from the left,
front: Dr Marietjie Schutte-Smith, Dr Alice Brink
(both scholars from the UFS Prestige
Scholar Programme), and Dr Truidie Venter (all three
are Thuthuka-funded researchers).
Back: Prof André Roodt and Dr Johan Venter.
Photo: Supplied

Imagine that you have been diagnosed with bone cancer and only have six months to live. You are in a wheelchair because the pain in your legs is so immense that you can’t walk anymore – similar to a mechanism eating your bones from the inside.

You are lucky though, since you could be injected with a drug to control the pain so effective that you will be able to get out of the wheelchair within a day-and-a-half and be able to walk again. Real-life incidents like these provide intense job satisfaction to Prof André Roodt, Head of Inorganic Chemistry at the University of the Free State (UFS). The research, which is conducted by the Inorganic Group at the UFS, contributes greatly to the availability of pain therapy that does not involve drugs, but improves the quality of life for cancer patients.

The research conducted by the Inorganic Group under the leadership of Prof Roodt, plays a major role in the clever design of model medicines to better detect and treat cancer.

The Department of Chemistry is one of approximately 10 institutions worldwide that conducts research on chemical mechanisms to identify and control cancer. “The fact that we are able to cooperate with the Departments of Nuclear Medicine and Medical Physics at the UFS, the Animal Research Centre, and other collaborators in South Africa and abroad, but especially the methodology we utilise to conduct research (studying the chemical manner in which drugs are absorbed in cancer as well as the time involved), enhances the possibility of making a contribution to cancer research,” says Prof Roodt.

Technique to detect cancer spots on bone
According to the professor, there are various ways of detecting cancer in the body. Cancer can, inter alia, be identified by analysing blood, X-rays (external) or through an internal technique where the patient is injected with a radioactive isotope.

Prof Roodt explains: “The doctor suspects that the patient has bone cancer and injects the person with a drug consisting of an isotope (only emits X-rays and does no damage to tissue) that is connected to a phosphonate (similar to those used for osteoporosis). Once the drug is injected, the isotope (Technetium-99m) moves to the spot on the bone where the cancer is located. The gamma rays in the isotope illuminate the area and the doctor can see exactly where treatment should be applied. The Technetium-99m has the same intensity gamma rays as normal X-rays and therefore operates the same as an internal X-ray supply.” With this technique, the doctor can see where the cancer spots are within a few hours.

The same technique can be used to identify inactive parts of the brain in Alzheimer patients, as well as areas of the heart where there is no blood supply or where the heart muscle is dead.

Therapeutic irradiation of cancer
For the treatment of pain connected with cancer, the isotope Rhenium-186 is injected. Similar to the manner in which the Technetium-99m phosphonate compound is ingested into the body, the Rhenium-186 phosphonate travels to the cancer spots. Patients thus receive therapeutic irradiation – a technique known as palliative therapy, which is excellent for treating pain. A dosage of this therapy usually lasts for about two months.

The therapy is, however, patient specific. The dosages should correspond with the occurrence and size of cancer spots in the patient’s body. First, the location of the cancer will be determined by means of a technetium scan. After that, the size of the area where the cancer occurs has to be determined. The dosage for addressing total pain distribution will be calculated according to these results.

Technique to detect cancer spots on soft tissue
Another technique to detect cancer as spots on bone or in soft tissue and organs throughout the body is by utilising a different type of irradiation, a so-called PET isotope. The Fluor-18 isotope is currently used widely, and in Pretoria a machine called a cyclotron was produced by Dr Gerdus Kemp, who is a former PhD graduate from the Inorganic Research Group. The F-18 is then hidden within a glucose molecule and a patient will be injected with the drug after being tranquillised and after the metabolism has been lowered considerably. The glucose, which is the ‘food' that cancer needs to grow, will then travel directly to the cancer area and the specific area where the cancer is located will thus be traced and ‘illuminated’ by the Fluor-18, which emits its own 'X-rays'.

In the late 80s, Prof Roodt did his own postdoctoral study on this research in the US. He started collaborating with the Department of Nuclear Medicine at the UFS in the early 90s, when he initiated testing for this research.

Through their research of more than 15 years, the Inorganic Group in the Department of Chemistry has made a major contribution to cancer research. Research on mechanisms for the detection of cancer, by designing new clever chemical agents, and the chemical ways in which these agents are taken up in the body, especially contributes to the development in terms of cancer therapy and imaging, and has been used by a number of hospitals in South Africa.

The future holds great promise
Prof Roodt and his team are already working on a bilateral study between the UFS and Kenya. It involves the linking of radio isotopes, as mentioned above, to known natural products (such as rooibos tea), which possess anti-cancer qualities.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept